166 related articles for article (PubMed ID: 36263945)
1. Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by Fragment-Based Drug Discovery.
Narayanan D; Tran KT; Pallesen JS; Solbak SMØ; Qin Y; Mukminova E; Luchini M; Vasilyeva KO; González Chichón D; Goutsiou G; Poulsen C; Haapanen N; Popowicz GM; Sattler M; Olagnier D; Gajhede M; Bach A
J Med Chem; 2022 Nov; 65(21):14481-14526. PubMed ID: 36263945
[TBL] [Abstract][Full Text] [Related]
2. Development of a Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay for the Inhibition of Keap1-Nrf2 Protein-Protein Interaction.
Lee S; Abed DA; Beamer LJ; Hu L
SLAS Discov; 2021 Jan; 26(1):100-112. PubMed ID: 32564647
[TBL] [Abstract][Full Text] [Related]
3. Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds.
Pallesen JS; Narayanan D; Tran KT; Solbak SMØ; Marseglia G; Sørensen LME; Høj LJ; Munafò F; Carmona RMC; Garcia AD; Desu HL; Brambilla R; Johansen TN; Popowicz GM; Sattler M; Gajhede M; Bach A
J Med Chem; 2021 Apr; 64(8):4623-4661. PubMed ID: 33818106
[TBL] [Abstract][Full Text] [Related]
4. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
[TBL] [Abstract][Full Text] [Related]
5. Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Protein-Protein Interaction.
Zhang Y; Shi Z; Zhou Y; Xiao Q; Wang H; Peng Y
J Med Chem; 2020 Aug; 63(15):7986-8002. PubMed ID: 32233486
[TBL] [Abstract][Full Text] [Related]
6. Medicinal Chemistry Insights into the Development of Small-Molecule Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitors.
Zhao Z; Dong R; You Q; Jiang Z
J Med Chem; 2023 Jul; 66(14):9325-9344. PubMed ID: 37441735
[TBL] [Abstract][Full Text] [Related]
7. Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.
Davies TG; Wixted WE; Coyle JE; Griffiths-Jones C; Hearn K; McMenamin R; Norton D; Rich SJ; Richardson C; Saxty G; Willems HM; Woolford AJ; Cottom JE; Kou JP; Yonchuk JG; Feldser HG; Sanchez Y; Foley JP; Bolognese BJ; Logan G; Podolin PL; Yan H; Callahan JF; Heightman TD; Kerns JK
J Med Chem; 2016 Apr; 59(8):3991-4006. PubMed ID: 27031670
[TBL] [Abstract][Full Text] [Related]
8. Interaction Energetics and Druggability of the Protein-Protein Interaction between Kelch-like ECH-Associated Protein 1 (KEAP1) and Nuclear Factor Erythroid 2 Like 2 (Nrf2).
Zhong M; Lynch A; Muellers SN; Jehle S; Luo L; Hall DR; Iwase R; Carolan JP; Egbert M; Wakefield A; Streu K; Harvey CM; Ortet PC; Kozakov D; Vajda S; Allen KN; Whitty A
Biochemistry; 2020 Feb; 59(4):563-581. PubMed ID: 31851823
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 protein-protein interaction inhibitors for inflammatory conditions.
Lu MC; Shao HL; Liu T; You QD; Jiang ZY
Eur J Med Chem; 2020 Dec; 207():112734. PubMed ID: 32866756
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions.
Jiang ZY; Lu MC; You QD
J Med Chem; 2016 Dec; 59(24):10837-10858. PubMed ID: 27690435
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of 1,4-bis(arylsulfonamido)-benzene or naphthalene-N,N'-diacetic acids with varying C2-substituents as inhibitors of Keap1-Nrf2 protein-protein interaction.
Lee S; Abed DA; Nguyen MU; Verzi MP; Hu L
Eur J Med Chem; 2022 Jul; 237():114380. PubMed ID: 35462166
[TBL] [Abstract][Full Text] [Related]
12. Advances in developing noncovalent small molecules targeting Keap1.
Barreca M; Qin Y; Cadot MEH; Barraja P; Bach A
Drug Discov Today; 2023 Dec; 28(12):103800. PubMed ID: 37852355
[TBL] [Abstract][Full Text] [Related]
13. Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
Pallesen JS; Tran KT; Bach A
J Med Chem; 2018 Sep; 61(18):8088-8103. PubMed ID: 29750408
[TBL] [Abstract][Full Text] [Related]
14. Emerging Screening Approaches in the Development of Nrf2-Keap1 Protein-Protein Interaction Inhibitors.
Leung CH; Zhang JT; Yang GJ; Liu H; Han QB; Ma DL
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31509940
[TBL] [Abstract][Full Text] [Related]
15. Screening approaches for the identification of Nrf2-Keap1 protein-protein interaction inhibitors targeting hot spot residues.
Asano W; Hantani R; Uhara T; Debaene F; Nomura A; Yamaguchi K; Adachi T; Otake K; Harada K; Hantani Y
SLAS Discov; 2024 Mar; 29(2):100125. PubMed ID: 37935317
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel inhibitors of Keap1/Nrf2 by a promising method combining protein-protein interaction-oriented library and machine learning.
Shimizu Y; Yonezawa T; Sakamoto J; Furuya T; Osawa M; Ikeda K
Sci Rep; 2021 Apr; 11(1):7420. PubMed ID: 33795749
[TBL] [Abstract][Full Text] [Related]
17. A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity.
Tran KT; Pallesen JS; Solbak SMØ; Narayanan D; Baig A; Zang J; Aguayo-Orozco A; Carmona RMC; Garcia AD; Bach A
J Med Chem; 2019 Sep; 62(17):8028-8052. PubMed ID: 31411465
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, and Structure-Activity Relationships of Indoline-Based Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-Like 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitors.
Zhou HS; Hu LB; Zhang H; Shan WX; Wang Y; Li X; Liu T; Zhao J; You QD; Jiang ZY
J Med Chem; 2020 Oct; 63(19):11149-11168. PubMed ID: 32902980
[TBL] [Abstract][Full Text] [Related]
19. Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1.
Unni S; Deshmukh P; Krishnappa G; Kommu P; Padmanabhan B
FEBS J; 2021 Mar; 288(5):1599-1613. PubMed ID: 32672401
[TBL] [Abstract][Full Text] [Related]
20. Fragment-Guided Discovery of Pyrazole Carboxylic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2 Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction.
Norton D; Bonnette WG; Callahan JF; Carr MG; Griffiths-Jones CM; Heightman TD; Kerns JK; Nie H; Rich SJ; Richardson C; Rumsey W; Sanchez Y; Verdonk ML; Willems HMG; Wixted WE; Wolfe L; Woolford AJ; Wu Z; Davies TG
J Med Chem; 2021 Nov; 64(21):15949-15972. PubMed ID: 34705450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
